Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and

RBC Capital analyst Luca Issi maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and rais

Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(1.08) per share which missed the analy

- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; P

- Company's third program to enter clinical development leveraging FORCE platform with the goal of d

Fifth Third Bancorp purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ: DYN) during the undefi

WALTHAM, Mass., July 24, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-

WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with

Pegasystems Inc (NASDAQ: PEGA) reported lower-than-expected earnings and sales, causing stocks to fa

Dyne Therapeutics stock fell after hours after pricing an upsized $375M public offering of common st

WALTHAM, Mass. , July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical

Gainers ENDRA Life Sciences (NASDAQ:NDRA) shares rose 10.8% to $5.94 during Tuesday's after-mar

WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-

Dyne gains momentum as FDA priority review for its lead DMD therapy and progress in its DM1 program

Dyne Therapeutics receives FDA Priority Review for z-rostudirsen in DMD, with a potential U.S. launc

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional imp

- Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Acce

Dyne Therapeutics is advancing a clinical-stage platform specifically targeting genetically driven n

Dyne Therapeutics focuses on high-potential therapies for rare neuromuscular diseases using its prop

Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss ma

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs

WALTHAM, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-

WALTHAM, Mass., June 18, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-

- Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50

- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTH

- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 -  WALT

DYN shares jump after the company files a BLA with the FDA for z-rostudirsen in Duchenne muscular dy

Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional impr

- 72-week trial will enroll approximately 90 participants; first site now open for enrollment -- Pri

Evercore ISI Group analyst Gavin Clark-Gartner maintains Dyne Therapeutics (NASDAQ:DYN) with a Ou

Bernstein analyst William Pickering maintains Dyne Therapeutics (NASDAQ:DYN) with a Market Perfor

Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.73) per share which beat the analyst

Dow Jones index up 200 points on Tuesday, NIO Inc. gained following better-than-expected financial r

Chardan Capital analyst Keay Nakae maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and mainta

US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer

HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1.48-

Dyne announced the results of new analyses of cardiac and pulmonary function amongst all DELIVER par

Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and

HC Wainwright & Co. analyst Ananda Ghosh maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy

Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.76) per share which beat the analyst

Sarepta stock drops after a wider loss, Elevidys sales fall 33%, and CEO retirement plans add fresh

JP Morgan analyst Tessa Romero maintains Dyne Therapeutics (NASDAQ:DYN) with a Neutral and lowers

- Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple

'Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy To Newborn Screeni

Evercore ISI Group analyst Gavin Clark-Gartner maintains Dyne Therapeutics (NASDAQ:DYN) with a Ou

Stifel analyst Paul Matteis maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the pr

Oppenheimer analyst Andreas Argyrides upgrades Dyne Therapeutics (NASDAQ:DYN) from Perform to Out

Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and